

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

















